The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
By Tom Wilbur | December 18, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients
By Nicole Longo | December 17, 2020
The New York Times recently ran a story that paints an inaccurate picture of the 340B program, contract pharmacy participation in the program and the biopharmaceutical industry’s commitment to the...
Read More
Increasing diversity at investigator sites could increase minority participation in clinical trials
By Guest Contributor | December 17, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
New report highlights biopharmaceutical industry’s commitment to D&I
By Abigail Lore | December 17, 2020
Today, PhRMA released a new report prepared by TEConomy Partners, LLC that provides insights into the efforts of biopharmaceutical companies to advance diversity & inclusion (D&I) in the...
Read More
Election insights: Voter priorities in the states
By Nick McGee | December 17, 2020
In the 2020 election, Americans nationwide cast their ballots with two major issues on their minds – the economy and coronavirus. Health care specific concerns centered on pre-existing conditions...
Read More
Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
By Stephen J. Ubl | December 16, 2020
This year our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections....
Read More
Insights from the election: Meeting voters where they are on health care
By Tom Wilbur | December 15, 2020
The 2020 election was defined by a wide range of unique, and in some cases, unprecedented factors. From a global pandemic to never before seen rates of mail-in ballot casting and record voter...
Read More
Key takeaways from new GAO report on covered entities’ lack of compliance with 340B requirements
By Nicole Longo | December 15, 2020
In case you missed it, the Government Accountability Office (GAO) released a new report looking at the 340B program and the mechanisms the government has to help ensure compliance with the...
Read More
Report: More than 1,300 medicines and vaccines in development to help fight cancer
By Andrew Powaleny | December 15, 2020
Over the last 30 years, significant progress has been made in the fight against cancer. Researchers have expanded their understanding of how cancer develops and how to target medicines for...
Read More
New analysis finds stark difference in coverage of breast cancer medicines for seniors in the United States and England
By Nicole Longo | December 10, 2020
In the United States, seniors and people with disabilities enjoy broad coverage of physician-administered medicines under Medicare Part B because the program relies on market competition to...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
